Advanced search
Publication Cover
mAbs Volume 8, 2016 - Issue 3
Submit an article Journal homepage
2,436
Views
39
CrossRef citations to date
0
Altmetric
Reports

Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2

Nikolai SiebertDepartment of Pediatric Oncology and Hematology, University Medicine Greifswald, Greifswald, Germany
,
Christin EgerDepartment of Pediatric Oncology and Hematology, University Medicine Greifswald, Greifswald, Germany
,
Diana SeidelDepartment of Pediatric Oncology and Hematology, University Medicine Greifswald, Greifswald, Germany
,
Madlen JüttnerDepartment of Pediatric Oncology and Hematology, University Medicine Greifswald, Greifswald, Germany
,
Maxi ZumpeDepartment of Pediatric Oncology and Hematology, University Medicine Greifswald, Greifswald, Germany
,
Danilo WegnerDepartment of Clinical Pharmacology of the Center of Drug Absorption and Transport, University Medicine Greifswald, Greifswald, Germany
,
Silke KietzDepartment of Pediatric Oncology and Hematology, University Medicine Greifswald, Greifswald, Germany
,
Karoline EhlertDepartment of Pediatric Oncology and Hematology, University Medicine Greifswald, Greifswald, Germany
,
Gareth J. VealNorthern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
,
Werner SiegmundDepartment of Clinical Pharmacology of the Center of Drug Absorption and Transport, University Medicine Greifswald, Greifswald, Germany
,
Michael WeissDepartment of Pharmacology, Martin Luther University, Halle, Germany
,
Hans LoibnerApeiron Biologics, Vienna, Austria
,
Ruth LadensteinChildren's Cancer Research Institute, Vienna, Austria
&
Holger N. LodeDepartment of Pediatric Oncology and Hematology, University Medicine Greifswald, Greifswald, GermanyCorrespondence[email protected]
 show all
Pages 604-616 | Received 16 Oct 2015, Accepted 05 Dec 2015, Published online: 08 Feb 2016

Reference List

  • Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens:a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737
  • Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 2007; 25:67-77; PMID:17364560; http://dx.doi.org/10.1080/07357900601130763
  • Yang RK, Sondel PM. Anti-GD2 Strategy in the Treatment of Neuroblastoma. Drugs Future 2010; 35:665; PMID:21037966; http://dx.doi.org/10.1358/dof.2010.035.08.1513490
  • Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34; PMID:20879881; http://dx.doi.org/10.1056/NEJMoa0911123
  • Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, Lewis G, Ladenstein R, Lode HN. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 2005; 42:1311-9; PMID:15950727; http://dx.doi.org/10.1016/j.molimm.2004.12.018
  • Ladenstein R, Weixler S, Baykan B, Bleeke M, Kunert R, Katinger D, Pribill I, Glander P, Bauer S, Pistoia V, et al. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients:a SIOPEN Phase 1 study. MAbs 2013; 5:801-9; PMID:23924804; http://dx.doi.org/10.4161/mabs.25215
  • Xiao WH, Yu AL, Sorkin LS. Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody. Pain 1997; 69:145-51; PMID:9060025; http://dx.doi.org/10.1016/S0304-3959(96)03280-0
  • Lode HN, Jensen C, Endres S, Pill L, Siebert N, Kietz S, et al. Immune activation and clinical responses following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in high-risk neuroblastoma patients. J Clin Oncol 2015; 32:5 13-6-.
  • Siebert N, Seidel D, Eger C, Brackrock D, Reker D, Schmidt M, Lode HN. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab. J Immunol Methods 2013; 398-399:51-9; PMID:24055592; http://dx.doi.org/10.1016/j.jim.2013.09.008
  • DeSilva B, Smith W, Weiner R, Kelley M, Smolec J, Lee B, Khan M, Tacey R, Hill H, Celniker A. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res 2003; 20:1885-900; PMID:14661937; http://dx.doi.org/10.1023/B:PHAM.0000003390.51761.3d
  • D'Argenio D, Schumitzky A, Wang X. ADAPT 5 User's Guide:Pharmacokinetic/Pharmacodynamic Systems Analysis Software 2009. Biomedical Simulations Resource Los Angeles, CA
  • Siebert N, Eger C, Seidel D, Juttner M, Lode HN. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO. J Immunol Methods 2014; 407:108-15; PMID:24727144; http://dx.doi.org/10.1016/j.jim.2014.04.001
  • Lode HN, Schmidt M, Seidel D, Huebener N, Brackrock D, Bleeke M, Reker D, Brandt S, Mueller HP, Helm C, et al. Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response. Cancer Immunol Immunother 2013; 62:999-1010; PMID:23591980; http://dx.doi.org/10.1007/s00262-013-1413-y
  • Siebert N, Seidel D, Eger C, Juttner M, Lode HN. Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody. PLoS One 2014; 9:e107692; PMID:25226154; http://dx.doi.org/10.1371/journal.pone.0107692
  • Desai AV, Fox E, Smith LM, Lim AP, Maris JM, Balis FM. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer Chemother Pharmacol 2014; 74:1047-55; PMID:25212536; http://dx.doi.org/10.1007/s00280-014-2575-9
  • Uttenreuther-Fischer MM, Huang CS, Yu AL. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients. Cancer Immunol Immunother 1995; 41:331-8; PMID:8635190; http://dx.doi.org/10.1007/BF01526552
  • Weiner LM, Surana R, Wang S. Monoclonal antibodies:versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205; http://dx.doi.org/10.1038/nri2744
  • DeNardo GL, Bradt BM, Mirick GR, DeNardo S. Human antiglobulin response to foreign antibodies:therapeutic benefit? Cancer Immunol Immunother 2003; 52:309-16; PMID:12700946

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.